Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Authors: Forde PM, Ettinger DS Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) deliver high response rates with relatively modest toxicity in patients with advanced EGFR-mutated non-small cell lung cancer. Despite this, nearly all tumors eventually develop resistance to first-line therapy. At present, the only standard treatment option for patients with acquired resistance is cytotoxic chemotherapy. In this article, we review the latest research into methods of targeting acquired resistance to EGFR TKI therapy, including third-generation EGFR TKIs that target the T790M resistance ...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Lies and truth.
Authors: Cheson BD PMID: 26352417 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The National Cancer Institute's Experimental Therapeutics Clinical Trials Network.
Authors: Ivy SP PMID: 26352418 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Authors: Sequist LV PMID: 26352419 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The shifting paradigm for transfusion of red blood cells.
Authors: Carson JL PMID: 26352420 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D, Turner K PMID: 26352421 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Rituximab maintenance in follicular lymphoma.
Authors: Barr PM PMID: 26352422 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Counterpoints: Do patients with multiple myeloma need maintenance treatment? Yes, but the proper candidates and schedule must be determined.
Authors: Berenson JR, Andreu-Vieyra C PMID: 26352423 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials.
Authors: Vesole DH, Siegel DS PMID: 26352424 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hepatocellular carcinoma: current questions and future directions.
Authors: Gish RG PMID: 26352425 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Key statistical concepts in cancer research.
Authors: Shi Q, Sargent DJ Abstract In this article, we provide a high-level overview of statistical concepts related to study design and data analysis in oncology research. These concepts are discussed for 2 main types of clinical research: (1) observational studies, which focus on biomarker discovery in order to predict disease risk and prognosis, and (2) prospectively designed, well-controlled clinical trials, which are critical for the development of new cancer treatments. Throughout the article, we emphasize the importance of appropriate design and prospectively determined analysis plans. We also hope to promo...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Review of treatment options for oligometastatic non-small cell lung cancer.
Authors: Folkert MR, Timmerman R Abstract Our understanding of metastatic disease is constantly evolving. Although outcomes for patients with stage IV non-small cell lung cancer (NSCLC) are poor, aggressive/radical local intervention may be effective in a subset of patients with limited or "oligometastatic" disease. Here we review and compare the range of available treatment options that are specific to oligometastatic NSCLC, and discuss potential directions of future clinical research. PMID: 26352427 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Inside my file cabinets.
Authors: Cheson BD PMID: 26352575 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Turner K PMID: 26352576 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Combination therapies for treating metastatic melanoma.
Authors: Tawbi H PMID: 26352577 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Authors: Mayer EL PMID: 26352578 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New developments in Richter syndrome.
Authors: Jain N PMID: 26352579 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New drugs in ovarian cancer.
Authors: Fleming GF PMID: 26352580 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of sorafenib in hepatocellular carcinoma.
Authors: Gholam P PMID: 26352581 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel therapeutic targets in multiple myeloma.
Authors: Cottini F, Anderson K Abstract Multiple myeloma (MM) is a disorder of clonal plasma cells that accumulate in the bone marrow and secrete a monoclonal protein detectable in the blood and/or urine. In the last decade, the outcome of patients with MM has markedly improved owing to the introduction of agents such proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide) as induction, consolidation, and maintenance strategies. Nonetheless, drug resistance leading to relapse commonly occurs, and novel therapies are urgently needed. In this review, we will describe the most promisi...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Curative treatment for severe sickle cell disease: allogeneic transplantation.
Authors: Oshrine B, Talano JA Abstract Sickle cell disease is an inherited hematologic disorder that in its severe form can result in substantial morbidity and early mortality. Patients with this disorder can suffer from severe pain, lung disease, and strokes, resulting in chronic debilitating conditions, end organ dysfunction, and organ failure. The health care costs of caring for these chronically ill patients are substantial. Allogeneic transplantation is a modality that has the potential to cure these patients. To date, matched sibling donor transplantation is widely accepted as a standard of care for pediatric...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Families with both Hodgkin lymphoma and multiple myeloma in their pedigrees.
Authors: Wiernik PH, Wickramasinghe D, Dutcher JP Abstract Reports of familial clustering of hematologic malignancies have appeared for decades, but the cause of this uncommon observation is still unknown. Most modern investigations support a genetic rather than an environmental explanation. Clinically, most pedigrees of families with familial hematologic malignancies demonstrate age of onset anticipation (ie, diagnosis at an earlier age in successive generations). The cause of anticipation is clear in some familial neurologic disorders (eg, trinucleotide repeat expansion in Huntington disease) but unclear in famil...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

FDA News.
Authors: Turner K PMID: 26352585 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The return of the emperor.
Authors: Cheson BD PMID: 26352767 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Monitoring lymphoma patients after therapy.
Authors: Roschewski M PMID: 26352768 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Authors: Shaw AT PMID: 26352769 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

PARP inhibitors in ovarian and other cancers.
Authors: Plummer R PMID: 26352770 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The new paradigm for transfusion of platelets.
Authors: Kaufman RM PMID: 26352771 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Authors: Dreicer R PMID: 26352772 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Authors: Li J, Armstrong AJ PMID: 26352773 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cancer immunology for the clinician.
Authors: Weiner LM Abstract Cancer immunotherapy is coming of age. It has become abundantly clear that immunotherapy-which has been described as treating the body's immune system so the immune system can treat the cancer-can be routinely effective, and may indeed cure advanced cancers. Accordingly, it is important to understand the basic, clinically relevant principles of cancer immunology to better prepare for an increasingly exciting future. The host immune system is the only active enemy faced by a malignant cell population as it develops. So it is helpful to think of the battle between the cancer cell populatio...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Non-clear cell renal cell carcinoma, part 1: histology.
This article (the first in a 2-part series) reviews the histology of RCC, whereas the second article reviews current targeted therapies approved for RCC, such as the vascular endothelial growth factor receptor tyrosine kinase inhibitors and the mammalian target of rapamycin inhibitors. Ongoing studies will provide more information regarding the role of these agents in non-clear cell RCC. PMID: 26352775 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 26352776 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat systemic light-chain amyloidosis.
Authors: Chaulagain CP, Comenzo RL Abstract Systemic light-chain (AL) amyloidosis is a multisystem disease characterized by organ toxicity and damage due to monoclonal free light chains, which are produced by a neoplastic clone of plasma cells in bone marrow. Current treatment strategies target the clone in order to decrease the production of the pathologic light chains and thereby stop or reverse organ toxicity and damage. AL amyloidosis remains a formidable and often incurable disease despite treatment options that include corticosteroids, cytotoxic chemotherapy, risk-adapted melphalan, autologous hematopoietic s...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Kidney Cancer Update The year in review in kidney cancer.
Authors: PMID: 26352778 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The "ASC(ST)O" meeting.
Letter From the Editor: The "ASC(ST)O" meeting. Clin Adv Hematol Oncol. 2015 Jun;13(6):341 Authors: Cheson BD PMID: 26352886 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Turner K PMID: 26352887 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Intermittent dosing in melanoma.
Authors: McMahon M PMID: 26352888 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

MET as a drug target.
Authors: Salgia R PMID: 26352889 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New therapies for polycythemia vera.
Authors: Verstovsek S PMID: 26352890 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Imaging techniques for hepatocellular carcinoma.
Authors: Sirlin C PMID: 26352891 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The future of kidney cancer treatment.
Authors: George DJ PMID: 26352892 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
Authors: Gingras I, Azim HA, Ignatiadis M, Sotiriou C Abstract Every cancer triggers an immune response that constitutes an important first-line protection against cancer progression. In breast cancer, there is an increasing awareness of the relationship between the immune system and tumor evolution. The tumor microenvironment is composed of a variety of immune cells that can control or arrest malignant progression. Chemotherapy and targeted therapy have been shown to modulate this immune microenvironment. Recently, tumor-infiltrating lymphocytes have emerged as a predictive and prognostic biomarker in early breast...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Non-clear cell renal cell carcinoma, part 2: therapy.
This article (the second in a 2-part series) reviews the current targeted therapies approved for RCC, such as the vascular endothelial growth factor receptor tyrosine kinase inhibitors and the mammalian target of rapamycin inhibitors. Ongoing studies will provide more information regarding the role of these agents in non-clear cell RCC. Ultimately, enhanced understanding of genetic triggers and the development of more tailored treatments remain imperative to improve outcomes in non-clear cell RCC. PMID: 26352894 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Renal cell carcinoma in patients with a personal or family history of hematologic malignancies.
Authors: Dutcher JP, Wiernik PH Abstract A little-appreciated association between renal cell carcinoma (RCC) and hematologic malignancies (HMs) has been reported for at least 20 years. The HM characteristically occurs first in patients with both neoplasms, and the large majority (94%) of these HMs are of B-cell origin. Furthermore, the majority of patients with RCC and an HM are male. Recently, we have noted an increased incidence of HMs in families of patients with RCC and are exploring this observation further. Here, we summarize our reports on the association between these neoplasms in individual patients and re...
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Reflections on Lugano.
Authors: Cheson BD PMID: 26353034 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Second-generation ALK inhibitors.
Authors: Mano H PMID: 26353035 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The potential threat to blood transfusion safety of emerging infectious disease agents.
Authors: Stramer SL PMID: 26353036 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in breast cancer from the 2015 American Society of Clinical Oncology annual meeting.
Authors: PMID: 26353037 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Stool DNA testing: a new, noninvasive option for colorectal cancer screening.
Authors: Ahlquist DA PMID: 26353038 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - November 18, 2015 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research